Literature DB >> 1815970

Relationship between renal function and disposition of oral cefixime.

M Dhib1, B Moulin, A Leroy, B Hameau, M Godin, R Johannides, J P Fillastre.   

Abstract

The pharmacokinetics of cefixime following a single oral dose of 200 mg have been investigated in 6 normal subjects and in 22 patients with various degrees of renal insufficiency. Serum and urine samples were collected between 0 and 72 h and were subjected to two methods of analysis: bioassay and HPLC. There was a linear relationship between the two sets of results from 228 samples. This result suggests that none of the metabolites, which may accumulate in uraemic patients, has antibacterial activity. In normal subjects, the peak serum level (Cmax) was 2.50 micrograms.ml-1 at 2.83 h (tmax); the apparent elimination half-life (t1/2) was 3.73 h; the apparent total body clearance (CL.f-1) was 154 ml.min-1, the mean renal clearance (CLR) was 39.1 ml.min-1 and the apparent fraction of the dose recovered in 24 h urine was 0.22. In uraemic patients, Cmax and tmax were slightly increased and t1/2 was increased to 12-14 h in patients with an endogenous creatinine clearance below 20 ml.min-1. The apparent volume of distribution was decreased. Apparent total and renal clearances were lower in proportion to the degree of renal insufficiency. Linear relationships were found between CL/f, CLR and creatinine clearance (CLCR). The findings suggest that the dose of cefixime needs to be reduced only in patients with severe renal failure.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1815970     DOI: 10.1007/BF00314988

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  Drug therapy. Clinical Pharmacokinetics (first of two parts).

Authors:  D J Greenblatt; J Kock-Weser
Journal:  N Engl J Med       Date:  1975-10-02       Impact factor: 91.245

2.  Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.

Authors:  E Singlas; A Leroy; E Sultan; M Godin; B Moulin; A M Taburet; M Dhib; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

3.  Pharmacokinetics of cefixime in the young and elderly.

Authors:  R D Faulkner; W Bohaychuk; R A Lanc; J D Haynes; R E Desjardins; A Yacobi; B M Silber
Journal:  J Antimicrob Chemother       Date:  1988-06       Impact factor: 5.790

4.  The pharmacokinetics of cefixime in the fasted and fed state.

Authors:  R D Faulkner; W Bohaychuk; J D Haynes; R E Desjardins; A Yacobi; B M Silber
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Mechanism of action of the new orally active cephalosporin FK027.

Authors:  Y Shigi; Y Matsumoto; M Kaizu; Y Fujishita; H Kojo
Journal:  J Antibiot (Tokyo)       Date:  1984-07       Impact factor: 2.649

6.  [Pharmacokinetics of cefotaxime and metabolites in uremic patients (author's transl)].

Authors:  J P Fillastre; R M Ings; A Leroy; M Godin; G Humbert
Journal:  Nephrologie       Date:  1982

7.  In vitro and in vivo antibacterial properties of FK 027, a new orally active cephem antibiotic.

Authors:  T Kamimura; H Kojo; Y Matsumoto; Y Mine; S Goto; S Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

8.  Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency.

Authors:  D R Guay; R C Meatherall; G K Harding; G R Brown
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

9.  Absolute bioavailability of cefixime in man.

Authors:  R D Faulkner; P Fernandez; G Lawrence; L L Sia; A J Falkowski; A I Weiss; A Yacobi; B M Silber
Journal:  J Clin Pharmacol       Date:  1988-08       Impact factor: 3.126

10.  Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin.

Authors:  H C Neu; N X Chin; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

  10 in total
  3 in total

Review 1.  Cefixime. A review of its therapeutic efficacy in lower respiratory tract infections.

Authors:  A Markham; R N Brogden
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

2.  Cefixime penetration in human renal parenchyma.

Authors:  A Leroy; B Oser; P Grise; G Humbert
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

3.  Pharmacokinetic study of an oral cephalosporin, cefdinir, in hemodialysis patients.

Authors:  A Hishida; K Ohishi; S Nagashima; M Kanamaru; M Obara; A Kitada
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.